Bridgeway Capital Management, LLC Neoleukin Therapeutics, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.4 - $0.55 $3,520 - $4,840	-8,800 Reduced 10.5%	75,000 $38,000
Q3 2022 Nov 14, 2022	BUY	$0.69 - $1.33 $57,821 - $111,454	83,800 New	83,800 $54,000
Q2 2022 Aug 15, 2022	SELL	$0.92 - $2.25 $49,496 - $121,050	-53,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $92,536 - $281,374	53,800 New	53,800 $101,000
Q2 2020 Aug 14, 2020	SELL	$9.95 - $17.05 $348,250 - $596,750	-35,000 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$6.12 - $13.64 $520,200 - $1.16 Million	-85,000 Reduced 70.83%	35,000 $398,000
Q4 2019 Feb 14, 2020	SELL	$2.65 - $12.72 $26,500 - $127,200	-10,000 Reduced 7.69%	120,000 $1.48 Million
Q3 2019 Nov 14, 2019	BUY	$2.33 - $3.76 $302,900 - $488,800	130,000 New	130,000 $371,000

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.